AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 32580803 — intervention group
Group type: COMPARATOR
Intervention: 0.12% nPP, 3.8% calcium, 2415 IU/kg vitamin D3, 2000 FTU/kg phytase
Number of subjects: 504
Study 35714273 — intervention group
Group type: EXPERIMENTAL
Intervention: Inactivated enterovirus 71 (EV71) vaccine, administered in two doses on day 0 and 28
Number of subjects: 3000
Study 33341239 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin plus radiotherapy (CRT)
Number of subjects: 146
Study 33341239 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy alone (RT)
Number of subjects: 146
Study 33341239 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline Karnofsky performance status (KPS) <90%
Number of subjects: 146
Study 33341239 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline hemoglobin <10 mg/dL
Number of subjects: 146
Study 32163672 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-invasive telemedical care (NITC)
Number of subjects: 2248
Study 32163672 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (control)
Number of subjects: 2248
Study 35431966 — intervention group
Group type: EXPERIMENTAL
Intervention: Osimertinib plus Yiqi-Yangyin-Jiedu decoction (O+YYJD)
Number of subjects: 314
Study 35431966 — intervention group
Group type: COMPARATOR
Intervention: Osimertinib plus placebo (O+placebo)
Number of subjects: 314
Study 34129232 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic supplement containing Lactobacillus acidophilus and Bifidobacterium animalis lactis
Number of subjects: 100
Study 34129232 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 33494374 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment with DAPI at a concentration of 10 µg/mL in 0.02% saponin or 0.1% Tween‐20 containing Hanks balanced salt solution for 30 min at room temperature
Number of subjects: 0
Study 33494374 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunocytochemical examination to visualize serotonin distribution
Number of subjects: 0
Study 33494374 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment with alkaline phosphatases
Number of subjects: 0
Study 34971222 — intervention group
Group type: EXPERIMENTAL
Intervention: Telemedicine remote cognitive testing
Number of subjects: 60
Study 34971222 — intervention group
Group type: COMPARATOR
Intervention: Face-to-face cognitive testing
Number of subjects: 60
Study 32628146 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate revascularization
Number of subjects: 0
Study 32628146 — intervention group
Group type: COMPARATOR
Intervention: Initially conservative treatment
Number of subjects: 0
Study 35672178 — intervention group
Group type: EXPERIMENTAL
Intervention: FluCyD-vac (9 μg of HA/strain and 20% w/v of HP-β-CyD)
Number of subjects: 36
Study 35672178 — intervention group
Group type: COMPARATOR
Intervention: Flu-vac (15 μg of HA/strain)
Number of subjects: 36
Study 35672178 — intervention group
Group type: EXPERIMENTAL
Intervention: FluCyD-vac
Number of subjects: 36
Study 34601838 — intervention group
Group type: EXPERIMENTAL
Intervention: SVV 9% group (liberal fluid therapy with SVV ≤9%)
Number of subjects: 80
Study 34601838 — intervention group
Group type: COMPARATOR
Intervention: SVV 14% group (restrictive fluid therapy with SVV ≤14%)
Number of subjects: 80
Study 32690591 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimally invasive surgery
Number of subjects: 549
Study 32690591 — intervention group
Group type: COMPARATOR
Intervention: Laparotomy
Number of subjects: 549
Study 35435426 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Number of subjects: 80
Study 35435426 — intervention group
Group type: COMPARATOR
Intervention: Remifentanil
Number of subjects: 80
Study 33427765 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 mg/kg ibalizumab q2wk
Number of subjects: 82
Study 33427765 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg/kg ibalizumab weekly for 9 weeks, then q2wk
Number of subjects: 82
Study 33427765 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 82
Study 34189992 — intervention group
Group type: EXPERIMENTAL
Intervention: MYmind program (n=15)
Number of subjects: 30
Study 34189992 — intervention group
Group type: COMPARATOR
Intervention: Wait-list group (n=15)
Number of subjects: 30
Study 33534427 — intervention group
Group type: EXPERIMENTAL
Intervention: 1,000 mg of borage oil rich in gamma-linolenic acid + vitamin E (drug)
Number of subjects: 96
Study 33534427 — intervention group
Group type: COMPARATOR
Intervention: Only vitamin E (placebo)
Number of subjects: 96
Study 32342562 — intervention group
Group type: EXPERIMENTAL
Intervention: Genome Sequencing (GS) immediately with concurrent standard of care (SoC) testing
Number of subjects: 34
Study 32342562 — intervention group
Group type: COMPARATOR
Intervention: Genome Sequencing (GS) delayed after 4 months of standard of care (SoC) testing
Number of subjects: 34
Study 32342562 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate GS group
Number of subjects: 34
Study 32342562 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined GS and SoC approaches
Number of subjects: 34
Study 35874588 — intervention group
Group type: EXPERIMENTAL
Intervention: Threshold Inspiratory Muscle Training (IMT) - 30 inspiratory breaths at 40% of baseline maximal inspiratory pressure (MIP) twice daily for 8 weeks
Number of subjects: 60
Study 35874588 — intervention group
Group type: COMPARATOR
Intervention: Incentive Spirometry (IS) - 30 breaths with sustained maximum inspiration twice daily for 8 weeks
Number of subjects: 60
Study 35874588 — intervention group
Group type: COMPARATOR
Intervention: Control group - no training device for 8 weeks
Number of subjects: 60
Study 33399410 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet-rich plasma treatment
Number of subjects: 44
Study 33399410 — intervention group
Group type: COMPARATOR
Intervention: Control group (topical glyceryl trinitrate)
Number of subjects: 44
Study 35982223 — intervention group
Group type: EXPERIMENTAL
Intervention: anodal tDCS
Number of subjects: 40
Study 35982223 — intervention group
Group type: EXPERIMENTAL
Intervention: theta tACS
Number of subjects: 40
Study 35982223 — intervention group
Group type: EXPERIMENTAL
Intervention: theta-oscillatory tDCS (otDCS)
Number of subjects: 40
Study 35982223 — intervention group
Group type: COMPARATOR
Intervention: sham stimulation
Number of subjects: 40
Study 32081221 — intervention group
Group type: EXPERIMENTAL
Intervention: Bladder catheterization (group A)
Number of subjects: 160
Study 32081221 — intervention group
Group type: COMPARATOR
Intervention: As-needed catheterization (group B)
Number of subjects: 160
Study 34617803 — intervention group
Group type: COMPARATOR
Intervention: SFFH from days 0 to 2 after fracture (Group B)
Number of subjects: 54
Study 34617803 — intervention group
Group type: EXPERIMENTAL
Intervention: SFFH from days 3 to 9 (Group C)
Number of subjects: 54
Study 34617803 — intervention group
Group type: EXPERIMENTAL
Intervention: SFFH from days 10 to 14 (Group D)
Number of subjects: 54
Study 34617803 — intervention group
Group type: EXPERIMENTAL
Intervention: Group B + interleukin 1 receptor antagonist (IL-1Ra) (Group E)
Number of subjects: 54
Study 34617803 — intervention group
Group type: EXPERIMENTAL
Intervention: Group B + doxycycline (Group F)
Number of subjects: 54
Study 34107543 — intervention group
Group type: EXPERIMENTAL
Intervention: Health Information Exchange (HIE) with advice from specialists (n=518, 38% male, mean age 76±7 years)
Number of subjects: 1092
Study 34107543 — intervention group
Group type: COMPARATOR
Intervention: No advice from specialists (Control group) (n=521, 39% male, mean age 75±7 years)
Number of subjects: 1092
Study 33167911 — intervention group
Group type: EXPERIMENTAL
Intervention: Thiamine 200 mg every 12 hours for 7 days
Number of subjects: 50
Study 33167911 — intervention group
Group type: COMPARATOR
Intervention: Placebo every 12 hours for 7 days
Number of subjects: 50
Study 35093666 — intervention group
Group type: EXPERIMENTAL
Intervention: Biofeedback training via a mobile insole system (Loadsol®)
Number of subjects: 24
Study 35093666 — intervention group
Group type: COMPARATOR
Intervention: Conventional training using a bathroom scale
Number of subjects: 24
Study 33251643 — intervention group
Group type: EXPERIMENTAL
Intervention: Empagliflozin 10 mg/day
Number of subjects: 79
Study 33251643 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 79
Study 32368972 — intervention group
Group type: EXPERIMENTAL
Intervention: ABCB1 variants (rs1128503, rs2032582, rs1045642)
Number of subjects: 131
Study 32368972 — intervention group
Group type: EXPERIMENTAL
Intervention: VDR variants (rs11568820, rs1540339, rs1544410, rs2228570, rs3782905, rs7975232)
Number of subjects: 131
Study 32368972 — intervention group
Group type: EXPERIMENTAL
Intervention: TPMT variants (rs1142345, rs1800460)
Number of subjects: 131
Study 34913089 — intervention group
Group type: EXPERIMENTAL
Intervention: Conservative fluid administration and active deresuscitation (removal of accumulated fluid using diuretics or ultrafiltration)
Number of subjects: 180
Study 34913089 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 180
Study 34913089 — intervention group
Group type: EXPERIMENTAL
Intervention: Conservative fluid administration and active deresuscitation
Number of subjects: 180
Study 32809843 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled AZD1419 (1, 4, or 8 mg; n=40)
Number of subjects: 81
Study 32809843 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n=41)
Number of subjects: 81
Study 34171086 — intervention group
Group type: EXPERIMENTAL
Intervention: WOOP intervention (spousal care partners received WOOP training immediately after baseline)
Number of subjects: 90
Study 34171086 — intervention group
Group type: COMPARATOR
Intervention: Control group (spousal care partners received WOOP training after a 3-month follow-up interview)
Number of subjects: 90
Study 34462184 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-directed rehabilitation (SDR) program using a smartwatch and mobile application
Number of subjects: 337
Study 34462184 — intervention group
Group type: COMPARATOR
Intervention: Formal physical therapy (PT)
Number of subjects: 337
Study 35080681 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium citrate (Utix sachets) administered three times per day until stent removal
Number of subjects: 115
Study 35080681 — intervention group
Group type: COMPARATOR
Intervention: No administration of Utix sachets (control group)
Number of subjects: 115
Study 36170002 — intervention group
Group type: EXPERIMENTAL
Intervention: InterWalk app-based interval walking training (IWT)
Number of subjects: 214
Study 36170002 — intervention group
Group type: COMPARATOR
Intervention: Standard care + InterWalk app-based interval walking training (IWT)
Number of subjects: 214
Study 36170002 — intervention group
Group type: COMPARATOR
Intervention: Standard care (StC)
Number of subjects: 214
Study 32056267 — intervention group
Group type: EXPERIMENTAL
Intervention: Single water swallows in the supine position
Number of subjects: 438
Study 32056267 — intervention group
Group type: COMPARATOR
Intervention: Single water swallows in the upright position
Number of subjects: 438
Study 32056267 — intervention group
Group type: COMPARATOR
Intervention: Supine position
Number of subjects: 438
Study 32056267 — intervention group
Group type: EXPERIMENTAL
Intervention: Single water swallows in the supine position with solid test meal
Number of subjects: 438
Study 34461742 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg ITI-214
Number of subjects: 27
Study 34461742 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg ITI-214
Number of subjects: 27
Study 34461742 — intervention group
Group type: EXPERIMENTAL
Intervention: 90 mg ITI-214
Number of subjects: 27
Study 34461742 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study 36281666 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose pioglitazone
Number of subjects: 3494
Study 36281666 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3494
Study 34340527 — intervention group
Group type: EXPERIMENTAL
Intervention: THX‐110 (Δ9‐THC 10 mg daily and PEA 800 mg daily)
Number of subjects: 16
Study 32701984 — intervention group
Group type: EXPERIMENTAL
Intervention: Verum acupuncture treatment
Number of subjects: 70
Study 32701984 — intervention group
Group type: EXPERIMENTAL
Intervention: Sham acupuncture
Number of subjects: 70
Study 32701984 — intervention group
Group type: COMPARATOR
Intervention: Waiting control group
Number of subjects: 70
Study 32701984 — intervention group
Group type: EXPERIMENTAL
Intervention: Verum acupuncture
Number of subjects: 70
Study 36435544 — intervention group
Group type: EXPERIMENTAL
Intervention: Narrative Therapy (NT)
Number of subjects: 72
Study 36435544 — intervention group
Group type: COMPARATOR
Intervention: Waitlist Control Group (WCG)
Number of subjects: 72
Study 33675344 — intervention group
Group type: EXPERIMENTAL
Intervention: EPA and DHA (3.36 g)
Number of subjects: 285
Study 33675344 — intervention group
Group type: COMPARATOR
Intervention: Control (none)
Number of subjects: 285
Study 35638561 — intervention group
Group type: EXPERIMENTAL
Intervention: CJM112 300 mg
Number of subjects: 66
Study 35638561 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66
Study 35746869 — intervention group
Group type: EXPERIMENTAL
Intervention: D1/D5-R antagonist (SCH-23390 hydrochloride)
Number of subjects: 0
Study 35746869 — intervention group
Group type: EXPERIMENTAL
Intervention: D2/D3-R antagonist (Eticlopride hydrochloride)
Number of subjects: 0
Study 35746869 — intervention group
Group type: COMPARATOR
Intervention: Placebo (0.9% saline)
Number of subjects: 0
Study 33028548 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral interarcuair decompression
Number of subjects: 174
Study 33028548 — intervention group
Group type: COMPARATOR
Intervention: Laminectomy
Number of subjects: 174
Study 35191215 — intervention group
Group type: EXPERIMENTAL
Intervention: LEU-PRO
Number of subjects: 83
Study 35191215 — intervention group
Group type: EXPERIMENTAL
Intervention: LEU-PRO+n-3
Number of subjects: 83
Study 35191215 — intervention group
Group type: COMPARATOR
Intervention: CON
Number of subjects: 83
Study 33058406 — intervention group
Group type: EXPERIMENTAL
Intervention: Body mass and BMI values from 2000 to 2006
Number of subjects: 2691
Study 33058406 — intervention group
Group type: EXPERIMENTAL
Intervention: Body mass and BMI values from 2006 to 2018
Number of subjects: 2691
Study 33058406 — intervention group
Group type: EXPERIMENTAL
Intervention: Motor tests results from 2000 to 2006
Number of subjects: 2691
Study 33058406 — intervention group
Group type: EXPERIMENTAL
Intervention: Motor tests results from 2006 to 2018
Number of subjects: 2691
Study 33058406 — intervention group
Group type: EXPERIMENTAL
Intervention: Body height changes from 2000 to 2018
Number of subjects: 2691
Study 33058406 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation between body mass/BMI and motor tests
Number of subjects: 2691
Study 32243432 — intervention group
Group type: EXPERIMENTAL
Intervention: Trier Social Stress Test (TSST)
Number of subjects: 12
Study 32243432 — intervention group
Group type: COMPARATOR
Intervention: No-stress control condition
Number of subjects: 12
Study 35636696 — intervention group
Group type: EXPERIMENTAL
Intervention: Osimertinib plus bevacizumab (80 mg daily + 15 mg/kg every 3 weeks)
Number of subjects: 122
Study 35636696 — intervention group
Group type: COMPARATOR
Intervention: Osimertinib monotherapy (80 mg daily)
Number of subjects: 122
Study 35636696 — intervention group
Group type: EXPERIMENTAL
Intervention: Osimertinib plus bevacizumab
Number of subjects: 122
Study 33860476 — intervention group
Group type: EXPERIMENTAL
Intervention: nonivamide‐nicoboxil cream
Number of subjects: 13
Study 33860476 — intervention group
Group type: COMPARATOR
Intervention: placebo cream
Number of subjects: 13
Study 35787482 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibandronate
Number of subjects: 124
Study 35787482 — intervention group
Group type: EXPERIMENTAL
Intervention: Denosumab
Number of subjects: 124
Study 34020669 — intervention group
Group type: EXPERIMENTAL
Intervention: Preconception care (PCC) services
Number of subjects: 591
Study 34020669 — intervention group
Group type: EXPERIMENTAL
Intervention: Folic acid supplementation
Number of subjects: 591
Study 34020669 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimizing psychological health
Number of subjects: 591
Study 34020669 — intervention group
Group type: EXPERIMENTAL
Intervention: Education status of mother
Number of subjects: 591
Study 34020669 — intervention group
Group type: EXPERIMENTAL
Intervention: Time spent to access nearby health facilities
Number of subjects: 591
Study 34020669 — intervention group
Group type: EXPERIMENTAL
Intervention: Availability of PCC unit
Number of subjects: 591
Study 34020669 — intervention group
Group type: EXPERIMENTAL
Intervention: Mother’s knowledge on PCC
Number of subjects: 591
Study 34020669 — intervention group
Group type: EXPERIMENTAL
Intervention: Being a model household
Number of subjects: 591
Study 34020669 — intervention group
Group type: EXPERIMENTAL
Intervention: Women’s autonomy in decision making
Number of subjects: 591
Study 32270385 — intervention group
Group type: EXPERIMENTAL
Intervention: KONTAKT© social skills group training
Number of subjects: 17
Study 36049698 — intervention group
Group type: EXPERIMENTAL
Intervention: Capsaicin cream
Number of subjects: 0
Study 36049698 — intervention group
Group type: COMPARATOR
Intervention: Hand cream (control group)
Number of subjects: 0
Study 34225789 — intervention group
Group type: EXPERIMENTAL
Intervention: degarelix plus best supportive care
Number of subjects: 198
Study 34225789 — intervention group
Group type: COMPARATOR
Intervention: placebo plus best supportive care
Number of subjects: 198
Study 36065786 — intervention group
Group type: EXPERIMENTAL
Intervention: BI 695501 for 48 weeks
Number of subjects: 0
Study 36065786 — intervention group
Group type: EXPERIMENTAL
Intervention: Humira for 24 weeks followed by BI 695501 for 24 weeks
Number of subjects: 0
Study 36065786 — intervention group
Group type: COMPARATOR
Intervention: Humira
Number of subjects: 0
Study 33888356 — intervention group
Group type: EXPERIMENTAL
Intervention: Intense neoadjuvant androgen deprivation therapy (ADT) followed by radical prostatectomy (RP)
Number of subjects: 201
Study 33888356 — intervention group
Group type: EXPERIMENTAL
Intervention: Intense neoadjuvant ADT
Number of subjects: 201
Study 32791015 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil supplementation for 83 days, average consumption 74% of the intervention period
Number of subjects: 7
Study 32791015 — intervention group
Group type: COMPARATOR
Intervention: Historical controls (N = 22)
Number of subjects: 7
Study 35649189 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan 100 mg daily
Number of subjects: 220
Study 35649189 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 220
Study 34726574 — intervention group
Group type: EXPERIMENTAL
Intervention: V114 administered concomitantly with QIV
Number of subjects: 1200
Study 34726574 — intervention group
Group type: COMPARATOR
Intervention: QIV plus placebo (non-concomitant group)
Number of subjects: 1200
Study 34384427 — intervention group
Group type: EXPERIMENTAL
Intervention: My Therapy (self-management program) in addition to usual care
Number of subjects: 2160
Study 34384427 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 2160
Study 34384427 — intervention group
Group type: EXPERIMENTAL
Intervention: My Therapy (self-management program)
Number of subjects: 2160
Study 35397432 — intervention group
Group type: EXPERIMENTAL
Intervention: Avelumab plus axitinib
Number of subjects: 0
Study 35397432 — intervention group
Group type: COMPARATOR
Intervention: Sunitinib
Number of subjects: 0
Study 32120870 — intervention group
Group type: EXPERIMENTAL
Intervention: Generic health literacy measured with the 'Measurement of Health Literacy Among Adolescents-Questionnaire' (MOHLAA-Q)
Number of subjects: 6608
Study 32120870 — intervention group
Group type: EXPERIMENTAL
Intervention: Health behavior, subjective health status, personal and social resources, socio-demographic and social factors, and health services use
Number of subjects: 6608
Study 32120870 — intervention group
Group type: EXPERIMENTAL
Intervention: Health literacy
Number of subjects: 6608
Study 36115928 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant radiotherapy (RT) for well-differentiated liposarcoma (n = 208)
Number of subjects: 3911
Study 36115928 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant radiotherapy (RT) for dedifferentiated liposarcoma (n = 290)
Number of subjects: 3911
Study 36115928 — intervention group
Group type: COMPARATOR
Intervention: Surgery alone
Number of subjects: 3911
Study 33232647 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative Pressure Wound Therapy (NPWT)
Number of subjects: 15
Study 33232647 — intervention group
Group type: COMPARATOR
Intervention: Non-Negative Pressure Wound Therapy (Non-NPWT)
Number of subjects: 15
Study 32951766 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual cervical manipulation
Number of subjects: 59
Study 32951766 — intervention group
Group type: EXPERIMENTAL
Intervention: Instrument-assisted cervical manipulation
Number of subjects: 59
Study 32951766 — intervention group
Group type: COMPARATOR
Intervention: Sham manipulation
Number of subjects: 59
Study 32951766 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 59
Study 32951766 — intervention group
Group type: EXPERIMENTAL
Intervention: All interventions
Number of subjects: 59
Study 36295786 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D3 supplementation (25,000 IU weekly)
Number of subjects: 90
Study 36295786 — intervention group
Group type: COMPARATOR
Intervention: Control group (no supplementation)
Number of subjects: 90
Study 33386530 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy for Chronic Pain (CBT‐CP) delivered either in person or by interactive voice response for 10 weeks
Number of subjects: 125
Study 33386530 — intervention group
Group type: EXPERIMENTAL
Intervention: Walking program as part of CBT‐CP
Number of subjects: 125
Study 33939497 — intervention group
Group type: EXPERIMENTAL
Intervention: Erenumab
Number of subjects: 955
Study 33939497 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 955
Study 32441709 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic partial middle‐turbinectomy in addition to endoscopic sinus surgery
Number of subjects: 90
Study 32441709 — intervention group
Group type: COMPARATOR
Intervention: Endoscopic sinus surgery without middle turbinectomy
Number of subjects: 90
Study 35139097 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine (HCQ)
Number of subjects: 127
Study 35139097 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 127